MMPOWER-3
Primary Mitochondrial Myopathy

A phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy (PMM) followed by an open-label treatment extension.

This trial will assess approximately 200 patients

**AGES 16-80**

Trial duration:

**PART I: PIVOTAL**

**PART II: OPEN-LABEL TREATMENT EXTENSION**

→ up to 32 weeks →

**TRIAL SITES**

APPROXIMATELY 30 SITES IN

North America
Europe

**ENDPOINTS**

**PRIMARY**
Distance walked (meters) in the 6-minute walk test
Total Fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

**SECONDARY**
Safety and tolerability
Patient- and clinician-reported outcomes

For more information, please visit ClinicalTrials.gov.